Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03040726 · ClinicalTrials.gov registry record · Phase 2
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
A Phase 2 study of Malignant Neoplasm and Nausea, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT03040726 is a Phase 2 study of Malignant Neoplasm and Nausea that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 53 participants, below the 513-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03040726, a Phase 2 study of Malignant Neoplasm and Nausea, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase II/III trial studies how well netupitant and palonosetron hydrochloride works in preventing chronic nausea and vomiting in patients with cancer. Netupitant and palonosetron hydrochloride may reduce nausea and vomiting.
Conditions Studied
Interventions
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Palonosetron
- DRUG Palonosetron Hydrochloride
- DRUG Netupitant
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-05-03 |
| Est. Completion | 2022-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03040726
The ClinicalTrials.gov registry entry for NCT03040726 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 513-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (90% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Malignant Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT03040726 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03040726 about?
NCT03040726 is a clinical study titled "Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer". This randomized phase II/III trial studies how well netupitant and palonosetron hydrochloride works in preventing chronic nausea and vomiting in patients with cancer. Netupitant and palonosetron hydrochloride may reduce nausea and vomiting.
What is the current status of trial NCT03040726?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2017-05-03. Estimated completion is 2022-02-14.
What conditions does trial NCT03040726 study?
This clinical trial studies the following conditions: Malignant Neoplasm, Nausea, Vomiting.
What interventions are being tested in trial NCT03040726?
The interventions under investigation include: Placebo (OTHER), Questionnaire Administration (OTHER), Palonosetron (DRUG), Palonosetron Hydrochloride (DRUG), Netupitant (DRUG).
Who is sponsoring clinical trial NCT03040726?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03040726 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Intraoperative Tumor Margin Identification With ICG Dye Imaging
RECRUITING · Phase 2
-
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
RECRUITING · Phase 2
-
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
RECRUITING · Phase 2
-
Dexamethasone in Controlling Dyspnea in Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.